Serum cytokine response to iron reduction in chronic hepatitis C patients
β Scribed by M. Kugelmas; W.D. Carey; C.J. McClain
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 47 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0896-548X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Interferon (IFN) alfa has been used widely for the treatment of chronic hepatitis C virus (HCV) infections but only a small number of patients treated have shown a sustained biochemical and virological response. Anti-envelope E1 and E2 antibody titers were assessed retrospectively before, during, an
Whether sustained biochemical response and absence of serum HCV RNA in the 6-12 months following suspension of interferon-β£ (IFN-β£) therapy reflect definitive viral clearance in patients with chronic hepatitis C virus (HCV) infection is controversial. To obtain more information on this topic, HCV RN
Interferon (IFN) receptor mRNA expression patterns in the liver have been shown to correlate with the effectiveness of IFN therapy in patients with hepatitis C virus (HCV) infection. However, it is not clear to what extent this factor contributes to the short (primary)-and long (sustained)term resul
A region associated with sensitivity to interferon (IFN) has been identified previously in the nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) genotype 1b. A study was undertaken to determine whether the presence of mutations in the NS5A 2209-2248 sequence could serve as a predictor of re
Detection and quantification of hepatitis C virus (HCV) RNA levels by using the standardized qualitative Amplicorβ’ HCV and quantitative Amplicor HCV Monitorβ’ assays (Roche Molecular Systems) were evaluated in 48 patients with chronic hepatitis C treated with interferon. Results were compared with an